OrbiMed’s InnovAge Holding INNV Stock Holding History

OrbiMed’s Portfolio INNV Stock Details INNV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-200,000	Closed	-$5.16M	–	168
2021 Q1	$5.16M	Buy	+200,000	New	+$4.93M	0.05%	142

Other funds holding INNV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

OrbiMed's INNV Position: Q2 2021 in Review

OrbiMed sold out of InnovAge Holding (INNV) in Q2 2021, closing a stake of 200,000 shares — an estimated $5.16M sold.

OrbiMed first reported a position in INNV in Q1 2021 and held it in 1 quarter. The position peaked at $5.16M in Q1 2021. 73 funds tracked by Wall St. Rank hold INNV as of Q2 2021.

OrbiMed reported no remaining InnovAge Holding position as of Q2 2021 after selling out during the quarter.
OrbiMed sold 200,000 InnovAge Holding shares in Q2 2021, an estimated $5.16M.
OrbiMed first reported a position in InnovAge Holding in Q1 2021 and held it in 1 quarter.
OrbiMed's InnovAge Holding position peaked at $5.16M in Q1 2021.
73 funds tracked by Wall St. Rank held InnovAge Holding as of Q2 2021.

Based on OrbiMed's 13F filing for Q2 2021, filed 16 Aug 2021.